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Abstract
This paper describes the progress made toward synthesis and characterization of
microencapsulated monomers dicyclopentadiene and cyclooctadiene, spectroscopic
evaluation of the microcapsules in an original self-healing material, and spectroscopic
distinctions between monomer and polymer.  Methods of characterization described
include infrared, Raman, and fluorescence spectroscopy as well as SEM images.  Brief
discussions of self-healing materials, ring-opening metathesis polymerization (ROMP), and
the mechanism and controlling parameters of microencapsulation are included.
Introduction: A ?Self-Healing? System
Inspired by biological systems, the “self-healing” concept has recently been applied to
synthetic materials as a way to repair micro-scale damage.  Self-healing materials, though
still in the early stages of design, may have applications in systems where detection and
repair of damage is limited, if not impossible.  For example, undetected microcracks in
space- and aircrafts can multiply over time, compromising the strength of the material and
often resulting in irreparable damage.1
The Original Design
A material that can “sense” its own degradation and repair itself automatically has already
been designed and has been shown to have enhanced mechanical properties.  The original
design includes the presence of microencapsulated monomers and catalyst particles in an
epoxy resin.  This scheme employs dicyclopentadiene (DCPD) as the monomer and a
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microcapsule outer shell composed of poly(urea-formaldehyde) and inner shell of ethylene
maleic anhydride copolymer (EMA) (Figure 1).
Figure 1. Composition of microcapsules.
Microcapsules containing the organic liquid-phase monomer are dispersed among a
polymeric matrix.  As a microcrack grows within the matrix, it punctures the microcapsule
shell, causing the monomer to flow into the crack.  Upon contact with a catalyst particle,
the monomer undergoes a polymerization reaction.  The cross-linked polymer product acts
as a solid-phase “glue” to reduce further crack propagation, which increases the lifetime of
the material.2a,b,c  The general mechanism is outlined in Figure 2.
Figure2. Self-healing mechanism; 1) propagation of microcrack; 2) puncture of the microcapsule shell; 3)
healing agent released in the crack.
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The success of this system, however, may be overshadowed by several limitations:
· DCPD has a melting point at 37°C.  The microencapsulated monomer must be in
the liquid phase in order to flow through the damage site.  The original design is
ineffective at low temperatures because DCPD is very likely in the solid phase.
Diffusion of solid phase DCPD into the crack is slow or unlikely to occur at all.
· Epoxy resins have strong adhesive properties. EPON 828, the epoxy resin
used in the original design, is strongly adhesive to a wide variety of substrates.
This property secures microcapsules within the matrix, preventing slippage and
increasing the effects of cracks and other disturbances on the microcapsule.  For
polymers with weak or no adhesive properties, the microcapsules may be allowed
more mobility within the matrix and might lose sensitivity to disturbances.  The
self-healing capabilities of microcapsules need to be tested in a non-adhesive
polymer matrix.
· The microcapsules are injected into a damage-prone site.   By intentionally
loading the microcapsules between two layers of epoxy followed by the instigation
of a “pre-crack,” the system is predisposed to cracking and sliding in this rift.  The
highly-controlled environment in which the self-healing capabilities of the system
are studied is not realistic for non-academic applications.
The Modified Design
In order to address these limitations, appropriate modifications have been made to the self-
healing system.  We are exploring the use of different monomers that can undergo Grubbs’
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catalyzed ring-opening metathesis polymerization (ROMP) at room temperature.  These
monomers necessarily have melting points below 23°C, preferably even lower in order to
accommodate use in space applications.  The monomers currently being explored as part
of our new self-healing design include 1,5-cyclooctadiene (COD), 1,3,5,7-
cyclooctatetraene, and cyclooctene, with melting points -70°C, -27°C, and -16°C,
respectively.  Successful microencapsulation of 1,5-cyclooctadiene has been achieved and
incorporated into our modified self-healing system.  Spectral evidence has been obtained
for the formation of DCPD as well as COD microcapsules (Figures 5-  ).
The epoxy matrix in which the microcapsules are embedded is being replaced by low-cost,
transparent polymers; including polystyrene (PS), polymethylmethacrylate (PMMA), and
polystyrene-polyisoprene-polystyrene block copolymer (SIS).  These polymers have
relatively good mechanical and electrical properties and good protection against gamma
radiation.3  The weak adhesive properties of these polymers allow analysis of the self-
healing capabilities in environments more realistic for aerospace applications.
The final modification from the original self-healing design is the sample preparation.  All
samples consist of a homogeneous polymer solution embedded with microcapsules and
catalyst.  Sample preparation is simple, making our methods more conducive to industrial
production.  And, cracks are not initiated manually, so the study more closely resembles
realistic conditions.  Preliminary results of material strength testing reveal enhanced
mechanical properties of our modified self-healing system, although these results will not
be discussed in this paper.
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Mechanism of Microcapsule Formation
Microencapsulated organic molecules are most commonly found in pharmaceutical drug
design as time-released agents.  Microencapsulated corrosion-prevention agents are often
incorporated in paint as well. And, microencapsulated fragrances are contained in
perfume, lotion, and “scratch-and-sniff” stickers.  The widespread applications for
microcapsules have made their formation a well-understood and easily-controlled process.
Our procedure for generating microcapsules is outlined by Brown, et al. 4  The mechanism
by which microcapsules form begins with the presence of the EMA copolymer in water.
Under continuous agitation, the organic monomer is introduced and drawn to the nonpolar
side of EMA.  EMA wraps itself around the monomer in a micelle-like formation,
shielding the organic phase from the aqueous phase.  Meanwhile, the poly(urea-
formaldehyde) condensation reaction has begun in the aqueous phase.  The polymer begins
growing at the emulsion interface as its solubility decreases, resulting in a highly cross-
linked shell wall.5a,b  This process is known as in situ microencapsulation (Figure 3).
Much of the urea-formaldehyde prepolymer formed in the aqueous phase begins attaching
itself to the outer shell.  This causes the rough topology of the microcapsules. Carefully
outlined by Brown, et al. are also the parameters that control microcapsule shell thickness,
surface morphology, and diameter. 4
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Controlling the Characteristics of Microcapsules
A brief discussion of the parameters that control the size, morphology, and shell wall
thickness is useful in order to understand the conditions under which the microcapsules
were prepared.  While still under investigation, some of the desired qualities and the
parameters necessary to achieve those qualities are highlighted.
Size
The optimum microcapsule diameter is yet to be determined.  However, the controlling
parameter is the agitation rate.  Producing micron-scale spheres (10-1000 µm) requires
200-2000 rpm agitation.4  At 550 rpm, the average diameter is about 200 µm at 79-92%
yield, according to Brown, et. al.  Our microcapsules were thus prepared using 450-550
rpm agitation rate.
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Morphology
In order to optimize any adhesive properties of the microcapsules to the polymeric matrix,
a rough surface morphology is desired.  The condensation reaction to produce poly(urea-
formaldehyde) requires either basic or acidic conditions.  When the reaction begins at pH
~3.5, a subsequent decrease to pH ~2.5 occurs naturally.  This accelerates the
polymerization rate, which increases the viscosity of the reaction mixture.  The organic-
aqueous interfacial tension is hence increased and urea-formaldehyde prepolymer clusters
aggregate at this interface.6  The formation of urea-formaldehyde aggregates can also be
increased by decreasing the agitation rate and/or adding smaller volumes of organic
monomer.4
Shell Wall Thickness
Because the formation of urea-formaldehyde aggregates is directly responsible for the
outer shell wall thickness, the same parameters that control surface morphology will
control the thickness.  However, the inner shell wall, which is composed of a thin layer of
EMA copolymer surrounded by cross-linked layers of poly(urea-formaldehyde), forms
early in the reaction and its characteristics are independent of subsequent reaction
variables. 4  This may be due to stoichiometric limitations of the reagents.  The poly(urea-
formaldehyde) may interact with the EMA micelle via hydrogen bonding, and the number
of these interactions is limited by available atoms at the interface.
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Characterization by Infrared Spectroscopy
Previous work by White, et. al. employed the use of infrared spectroscopy to characterize
the effectiveness of their self-healing system.  Using the appearance of a trans-double
bond appearing at 965 cm-1 as evidence of DCPD polymerization (Figure 4), the crack
plane within the epoxy resin was imaged and the infrared spectrum was collected on site.1
Figure 4. Ring-opening metathesis polymerization of DCPD.
The assembly of a thin film in the crack coupled with the appearance of the trans-double
bond stretch at 965 cm-1 proved that the material had in fact “self-healed.”  Gathering
spectral evidence at the site of damage in a material is not an easy task.  White, et. al.
obtained infrared spectra from a damaged surface.  Scanning electron micrograph (SEM)
images of the crack plane provided evidence for the thin polymeric film, which could then
be analyzed.  However, much of the microscale damage that occurs in materials is the
Grubbs' catalyst
n
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result of hidden internal cracks that cannot be imaged by microscopy.  This makes
analysis of the damage and proof of self-healing capabilities extremely difficult.  Under the
modified design of our self-healing system, several spectroscopic methods were explored
to evidence the polymerization of the monomer within the material.
The first effort mimicked the work of White, et. al., providing infrared spectral signatures
for dicyclopentadiene and its polymerized product.  The subsequent spectral signatures
were obtained for microencapsulated DCPD with and without the presence of Grubbs’
catalyst.  However, infrared spectral evidence for the presence of monomer or polymer
could not be obtained when the microcapsules were buried in the material matrix.
Shown in Figure 5 is the infrared spectrum of liquid-phase dicyclopentadiene.  The
intense, sharp peaks at 755 cm-1 and 727 cm-1 represent the cis-RCH=CHR bending
modes.
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Figure 5.  FTIR spectrum of liquid DCPD.
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Shown in Figure 6 is DCPD in the presence of second generation Grubbs’ catalyst.  The
diminishing of the peaks at 755 cm-1 and and 727 cm-1 as well as the growth of a new peak
at 976 cm-1 are evidence for the polymerization of DCPD.7  The new peak is
representative of the C-H bending mode of a trans-double bond.  These changes are
highlighted in Figure 7.
Dicyclopentadiene + Grubbs' Catalyst
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Figure 6.  FTIR spectrum of DCPD in the presence of Grubbs’ catalyst.
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Dicyclopentadiene: Monomer and Polymer
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Figure 7. Comparison of FTIR spectra of DCPD with and without the presence of Grubbs’ catalyst.
While the infrared spectrum for microencapsulated DCPD (Figure 8) clearly shows the
absence of the trans-double bond peak at 976 cm-1, the expected cis-double bond peaks at
755 cm-1 and 727 cm-1 are also absent.  The only evidence for the presence of
dicyclopentadiene within the microcapsule is the sharp peak at 668 cm-1 corresponding to
the -CH2 bending mode.  This peak is too prominent to represent the –CH2 associated
with poly(urea-formaldehyde). 5b
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Figure 8.  FTIR spectrum of microencapsulated DCPD.
Microencapsulated Dicyclopentadiene + Grubbs' Catalyst
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Figure 9.  FTIR spectrum of microencapsulated DCPD in the presence of Grubbs’ catalyst.
Figure 9 shows the appearance of a peak at 976 cm-1, though very weak and much broader
than expected.  Figure 10 highlights the differences between the spectra of DCPD
microcapsules with and without Grubbs’ catalyst.
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Microencapsulated Dicyclopentadiene: Monomer and Polymer
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DCPD Microcapsules DCPD Microcapsules + Grubbs'
Figure 10.  Comparison of FTIR spectra of DCPD microcapsules with and without the presence of
Grubbs’ catalyst.
To be sure that the presumed trans-double bond peak present in Figure 10 represents
polymerized DCPD, Figure 11 shows the IR spectrum of Grubbs’ second generation
catalyst.  There is no peak present between 1010 cm-1 and 929 cm-1.
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Figure 11. FTIR spectrum of Grubbs’ catalyst.
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Analogous methods to those used to determine the polymerization of DCPD can be used
to determine the polymerization of cyclooctadiene.  This monomer readily undergoes
ROMP in the presence of second generation Grubbs’ catalyst (Figure 12), and the
polymerized product contains long chains with primarily trans-double bonds.8
n
n
n
+
+
Grubbs' catalyst
Figure 12.  ROMP products of COD in the presence of second generation Grubbs’ catalyst; note that
many of these bonds undergo spontaneous cis-trans isomerization following the polymerization, resulting
in primarily trans- polymeric chains.
Figure 13 shows the IR spectrum of liquid COD.  The sharp, prominent peaks at 800 cm-1,
723 cm-1, 709 cm-1 and 652 cm-1 correspond to cis-RCH=CHR bending modes.  Their
broadening into a single peak at 739 cm-1 upon interaction with Grubbs’ catalyst is clear in
Figure 14, as is the appearance of a trans-double bond peak at 970 cm-1.
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Cyclooctadiene
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Figure 13. FTIR spectrum of liquid cyclooctadiene.
Cyclooctadiene + Grubbs' Catalyst
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Figure 14.  FTIR spectrum of cyclooctadiene in the presence of Grubbs’ catalyst.
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Cyclooctadiene: Monomer and Polymer
60
65
70
75
80
85
60070080090010001100120013001400
Wavenumbers (cm-1)
%
 T
ra
ns
m
itt
an
ce
COD COD + Grubbs
Figure 15.  Comparison of FTIR spectra of COD with and without the presence of Grubbs’ catalyst; note
that the y values of the COD + Grubbs’ spectrum were systematically increased by 70 units to highlight
the appearance of the trans-double bond peak.
The characterization of microencapsulated cyclooctadiene and its polymerization proved
quite successful.  Even in the presence of strong C-O and C-N stretches from the
poly(urea-formaldehyde), the appearance of the trans-double bond peak at 970 cm-1 is
very apparent (Figures 16-18).
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Microencapsulated Cyclooctadiene
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Figure 16.  FTIR spectrum of microencapsulated COD.
Microencapsulated Cyclooctadiene + Grubbs' Catalyst
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Figure 17.  FTIR spectrum of microencapsulated COD in the presence of Grubbs’ catalyst.
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Microencapsulated Cyclooctadiene: Monomer and Polymer
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Figure 18.  Comparison of microencapsulated COD with and without the presence of Grubbs’ catalyst.
Unsuccessful attempts were made to achieve infrared spectral evidence of DCPD and
COD polymerization from within PS, SIS, and PMMA polymeric matrices of the self-
healing materials.  These investigations are still active, but are hindered by heavy
absorption bands from these polymers in the “fingerprint” region of the infrared spectra.
The data obtained from infrared spectroscopy not only reveals the presence of
microencapsulated DCPD and COD, but can be used to distinguish each monomer from
its polymerized product.  While this method is useful for the characterization of
microcapsules and their contents, it proves futile once the microcapsules are embedded in
low concentrations into a polymer network.
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Characterization by Fluorescence
One useful property of the microcapsule shell is its intense fluorescence.  The confocal
image of the self-healing system (Figure 19) reveals the strong emission of the
microcapsules upon excitation with 543 nm light.  The red fluorescence is very likely due
to excitation of the microcapsule shell (poly(urea-formaldehyde)).  This explains its
presence on the outer circumference of the microcapsules and fragments in the polymer
matrix.
The apparent green “fluorescence” found almost exclusively within the microcapsule is
actually the reflection of the green laser from microencapsulated DCPD.  The appropriate
wavelength required to selectively excite DCPD was not available in the instrument from
which the image in Figure 19 was obtained.  The FV1000 is designed for biological
species, so the available lasers are limited to lower-energy wavelengths.  However,
selective excitation of DCPD could be obtained using a simple fluorometer.
Figure 19.  Confocal laser microscope image of poly(urea-formaldehyde) microcapsules filled with DCPD
in polystyrene-polyisoprene-polystyrene block copolymer; image collected from the Olympus FV1000.
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Dicyclopentadiene
-20
0
20
40
60
80
100
120
140
160
180
200 250 300 350 400 450 500 550
Wavelength (nm)
In
te
ns
ity
Emission Excitation
Figure 20.  Emission and excitation spectra of liquid DCPD; ? ex = 268 nm.
Excitation of liquid DCPD produced emission maxima at 360 nm and 522 nm (Figure 20).
These emission peaks were monitored during the excitation of microcapsules in order to
selectively excite the monomer from within the shell.
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Dicyclopentadiene Microcapsules
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Figure 20. Emission and excitation spectra of microcencapsulated DCPD; ? ex = 220 nm; note that the
intense peak at 450 nm is the result of an instrumental artifact.
The peak at 522 nm is weak, but evident, in the emission spectrum for microencapsulated
DCPD (Figure 21).  However, the peak at 360 nm is buried under more intense emission
peaks from the microcapsule shell.  The large emission at 628 nm supports the assignment
of red fluorescence in the confocal image to the poly(urea-formaldehyde) shell.
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Figure 22.  Emission spectrum of microencapsulated DCPD; ? ex = 320 nm.
Shown in Figure 22 is the selective excitation of microencapsulated DCPD, which can be
exploited in combination with confocal imaging in the future.  A material into which
microencapsulated DCPD is embedded can be imaged by a confocal lens and excited with
320 nm light in order to illuminate the monomer within the microcapsule.  Any cracks into
which the monomer has leaked will be illuminated as well, providing a profile of the
damage within the material.  The microcapsulated COD has not yet shown selective
fluorescence, but this goal is currently being pursued.
Fluorescence microscopy proves to be a powerful tool for imaging microcapsules in a
polymeric matrix.  Coupling the use of a confocal lens with selective excitation of each
component in the image plane may prove valuable for analysis of the damage that exists
beneath the surface.
Microencapsulated Dicyclopentadiene
-5
5
15
25
35
340 350 360 370 380 390 400 410 420 430 440
Wavelength (nm)
In
te
ns
ity
537
Characterization by Raman Spectroscopy
Poly(DCPD) can be distinguished from DCPD using Raman spectroscopy.  By monitoring
the emergence of a peak at 1660 cm-1over time, the extent of DCPD polymerization can
be determined.9  While other spectral distinctions can be made between monomer and
polymer, these changes are subtle.
Shown in Figure 23 is the Raman spectrum of microencapsulated DCPD, obtained by
focusing the laser inside the microcapsule.  The peaks in this spectrum differ systematically
from the literature by 100 cm-1.  Although the reason for this bathochromic shift has not
been determined, all attempts to confirm the presence of poly(DCPD) will be based upon
the emergence of a peak at 1560 cm-1.
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Figure 23.  Raman spectrum of microencapsulated DCPD.
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Unlike the infrared spectrum, the Raman spectrum obtained from microencapsulated
DCPD (Figure 23) is almost identical to that of its liberated form.  The coupling of the
Raman laser to a microscope minimizes any scattering from the microcapsule shell.
However, monitoring the polymerization of DCPD proved to be more difficult.  The
sample preparation (gentle crushing of the microcapsules with catalyst) necessitates the
presence of microcapsule shell and Grubbs’ catalyst in the liberated DCPD.  Determining
the optimum focus for the laser requires finding the polymer in the midst of the other
components.  Though repeated attempts were made to achieve this optimum focus, the
resulting Raman spectra were inconclusive.
Microencapsulated DCPD is barely detectable from within the poly(SIS) matrix.  Shown
in Figure 24 and 25 are the Raman spectra of poly(SIS) and a DCPD microcapsule within
poly(SIS) matrix.  The spectrum in Figure 25 contains peaks at 1514 cm-1 and 1467 cm-1,
corresponding to DCPD.  This is promising evidence for the detection of the monomer in
a self-healing system.  However, the large peak at 1567 cm-1 from poly(SIS) prohibits the
detection of poly(DCPD) within the matrix. Figure 26 highlights the differences between
the spectra in the region between 1450 cm-1 and 1550 cm-1.
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Polystyrene-polyisoprene-polystyrene Block Copolymer
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Figure 24.  Raman spectrum of poly(SIS).
Microencapsulated DCPD in poly(SIS)
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Figure 25.  Raman spectrum of microencapsulated DCPD within poly(SIS) matrix.
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Figure 26.   Highlighting the detection of microencapsulated DCPD within poly(SIS) matrix by the
appearance of peaks at 1514 cm-1 and 1467 cm-1.
Cyclooctadiene Microcapsules
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Figure 27.  Raman spectrum of microencapsulated COD.
The Raman spectrum for COD within the microcapsule resembles the spectrum predicted
in the literature for free COD.10  The same bathochromic shift of 100 cm-1 of
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microencapsulated monomer to liberated monomer was found for COD that was found
DCPD.
The preliminary results for the detection of microencapsulated cyclooctadiene are
encouraging (Figure 27).  However, no studies have been conducted to monitor the
polymerization of COD by Raman spectroscopy.  Hence, attempts to characterize
poly(COD) by Raman are currently under investigation.  Furthermore, attempts to detect
COD within a polymer matrix have been unsuccessful.
Characterization by Scanning Electron Micrograph
While literature containing similar syntheses4-6 was used as a prediction of the
characteristics of our microcapsules, analysis of SEM images confirmed these predictions.
Figures 28-33 show images containing representative samples from both DCPD and COD
microcapsules.
The image of a cracked microcapsule in Figure 28 shows clearly the rough surface
topology of the outer shell.  The microcapsule in Figure 29 has been pulled apart to reveal
the smooth inner membrane.  The image in Figure 30, along with similar images that
contain a representative group of microcapsules, was used to estimate the average
diameter of a DCPD microcapsule to be about 160 microns.
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Figure 28.  SEM image of a DCPD microcapsule. Figure 29.  SEM image of a DCPD microcapsule.
Figure 30.  SEM image of DCPD microcapsules.
The COD microcapsules, as revealed by the images in Figures 31-33, consisted of a
slightly smoother outer surface morphology and more free aggregated poly(urea-
formaldehyde).  The average microcapsule diameter was estimated to be about 50
microns.  Modifications to the synthesis of COD microcapsules are currently being
developed and applied to increase the diameter and the roughness of the outer shell.
Some of these modifications include a reduced agitation rate and a decreased volume of
COD.  Preliminary results suggest that these modifications are successful, but optimum
conditions for the synthesis of microencapsulated COD have yet to be determined.
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Figure 31.  SEM image of COD microcapsules. Figure 32.  SEM image of COD microcapsule
   Figure 33.  SEM image of COD microcapsules
Experimental
Synthesis of Dicyclopentadiene Microcapsules
In a 1000-mL beaker, 200 mL H2O and 50 mL 2.5 % wt. EMA copolymer were combined
under 350 rpm agitation, followed by the addition of 5.00 g urea, 0.50 g resorcinol, and
0.50 g ammonium chloride.  Several drops of 10% wt. NaOH were added to raise the pH
to 3.50 and 3 drops of 1-octanol were added to eliminate surface bubbles.  Sixty mL of
liquid DCPD were added and the reaction mixture was allowed to stabilize.  After 10
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minutes, 12.67 g of 37% aqueous formaldehyde were added.  The reaction was heated at a
rate of about 1°C per minute until it reached 55°C.  The agitation rate was increased to
550 rpm and continued under agitation for 6 hours.  After cooling, the microcapsules were
separated from the aqueous phase by suction filtration.
Synthesis of Cyclooctadiene Microcapsules
An analogous procedure to that of DCPD microcapsule synthesis was used to synthesize
COD microcapsules, with the following variations:
· The initial stirring rate was 750 rpm, which was decreased to 550 rpm upon
heating.
· Eighty mL of COD were added to the reaction mixture
· Agitation continued after heating for 4 hours.
Preparation of Modified Self-Healing Design
Twenty grams of poly(SIS) were dissolved in 50 mL toluene under agitation to achieve a
homogeneous mixture.  Then, 2.0 g microcapsules were dispersed in the mixture followed
by 0.001 g second generation Grubbs’ catalyst.  The mixture was poured onto silica-
coated glass microscope slides.
Sample Preparation and Instrument Specifications
All infrared spectra were collected from KBr samples and recorded on a Nicolet 510P
FTIR spectrometer.  The fluorescent confocal image was collected from an Olympus
FV1000 under operation of a Helium-Neon 543 nm laser.  Emission and excitation
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maxima were collected from a Perkin-Elmer LS50B fluorometer.  All Raman spectra were
collected with a Renishaw 1000B micro-Raman spectrometer under the operation of a 785
nm SDL diode laser.  SEM images were collected on gold-sputtered samples from LEO
1430 scanning electron micrograph.
Future Work
Having obtained partial FTIR, Raman, and fluorescence spectral profiles of
microencapsulated monomers DCPD and COD and poly(DCPD), I will focus my initial
effort on improving the detection of microencapsulated monomer within a poly(SIS)
matrix.  In addition, methods to distinguish polymer from monomer within the self-healing
material are currently being explored.  Once effective distinction of monomer and polymer
is achieved using the spectroscopic methods described in this paper, the capabilities of our
modified self-healing design can be better evaluated.  Spectroscopic evaluation of damage
in conjunction with mechanical testing will aid in the design of a material with enhanced
mechanical properties.
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